Data completeness
4/8 — Partial
Drug data last refreshed 31m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MITIGARE is an oral capsule formulation of colchicine, a small-molecule alkaloid approved in 2014 for gout treatment. It works by inhibiting neutrophil activation and migration through disruption of microtubule polymerization and inflammasome complex interference, thereby reducing IL-1β-mediated inflammation triggered by monosodium urate crystals.
$0.025BPart D
PeakStable
6.8 years to LOEProduct remains at peak commercial performance with no biosimilar or generic competition as of 2023; brand teams maintain stable, focused resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on MITIGARE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.